CBA-1535

N/A

Report date: 2026/03/19 17:16:34

Base Information

Drug NameCBA-1535

Drug Alias NameCBA-1535

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Trophoblast glycoproteinAnti-CD3

TargetsTrophoblast glycoproteinT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesChiome Bioscience Inc

China Registration ClassN/A

Develop Information

Active CompaniesChiome Bioscience Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[5]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A